Welcome to Hodoodo Chemicals

Levothyroxine sodium hydrate
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H534603

CAS#: 25416-65-3 (sodium hydrate)

Description: Levothyroxine sodium is a thyroid hormone.

Chemical Structure

Levothyroxine sodium hydrate

CAS# 25416-65-3 (sodium hydrate)

Instruction

Theoretical Analysis

Hodoodo Cat#: H534603
Name: Levothyroxine sodium hydrate
CAS#: 25416-65-3 (sodium hydrate)
Chemical Formula: C15H12I4NNaO5
Exact Mass: 816.68
Molecular Weight: 816.871
Elemental Analysis: C, 22.06; H, 1.48; I, 62.14; N, 1.71; Na, 2.81; O, 9.79

Price and Availability

Size	Price	Availability
1g	USD 150	2 Weeks
2g	USD 250	2 Weeks
5g	USD 450	2 Weeks
10g	USD 750	2 Weeks
25g	USD 1250	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 51-48-9 (free) 55-03-8 (sodium) 6106-07-6 (sodium pentahydrate) 25416-65-3 (sodium hydrate)

Synonym: Levothyroxine sodium hydrate

IUPAC/Chemical Name: L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, hydrate

InChi Key: ANMYAHDLKVNJJO-LTCKWSDVSA-M

InChi Code: InChI=1S/C15H11I4NO4.Na.H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;1H2/q;+1;/p-1/t12-;;/m0../s1

SMILES Code: N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O.[H]O[H].[Na+]

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 816.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017 Jan;55(1):6-18. doi: 10.1007/s12020-016-1199-8. Epub 2016 Dec 16. PMID: 27981511.

2: Skelin M, Lucijanić T, Amidžić Klarić D, Rešić A, Bakula M, Liberati-Čizmek AM, Gharib H, Rahelić D. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clin Ther. 2017 Feb;39(2):378-403. doi: 10.1016/j.clinthera.2017.01.005. Epub 2017 Jan 30. PMID: 28153426.

3: Dhillon-Smith RK, Middleton LJ, Sunner KK, Cheed V, Baker K, Farrell-Carver S, Bender-Atik R, Agrawal R, Bhatia K, Edi-Osagie E, Ghobara T, Gupta P, Jurkovic D, Khalaf Y, MacLean M, McCabe C, Mulbagal K, Nunes N, Overton C, Quenby S, Rai R, Raine-Fenning N, Robinson L, Ross J, Sizer A, Small R, Tan A, Underwood M, Kilby MD, Boelaert K, Daniels J, Thangaratinam S, Chan SY, Coomarasamy A. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. N Engl J Med. 2019 Apr 4;380(14):1316-1325. doi: 10.1056/NEJMoa1812537. Epub 2019 Mar 23. PMID: 30907987.

4: Ianiro G, Mangiola F, Di Rienzo TA, Bibbò S, Franceschi F, Greco AV, Gasbarrini A. Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur Rev Med Pharmacol Sci. 2014;18(4):451-6. PMID: 24610609.

5: Duntas LH, Jonklaas J. Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime. Adv Ther. 2019 Sep;36(Suppl 2):30-46. doi: 10.1007/s12325-019-01078-2. Epub 2019 Sep 4. PMID: 31485977; PMCID: PMC6822824.

6: Azran C, Porat D, Fine-Shamir N, Hanhan N, Dahan A. Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019 Feb;15(2):333-341. doi: 10.1016/j.soard.2019.01.001. Epub 2019 Jan 10. PMID: 30704913.

7: Chon DA, Reisman T, Weinreb JE, Hershman JM, Leung AM. Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. Thyroid. 2018 Apr;28(4):454-457. doi: 10.1089/thy.2017.0428. Epub 2018 Mar 28. PMID: 29589994; PMCID: PMC5905419.

8: Geer M, Potter DM, Ulrich H. Alternative schedules of levothyroxine administration. Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. PMID: 25694412.

9: Benvenga S, Carlé A. Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution. Adv Ther. 2019 Sep;36(Suppl 2):59-71. doi: 10.1007/s12325-019-01079-1. Epub 2019 Sep 4. PMID: 31485974; PMCID: PMC6822816.

10: Dhillon-Smith RK, Coomarasamy A. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Reply. N Engl J Med. 2019 Jul 11;381(2):190-191. doi: 10.1056/NEJMc1906509. PMID: 31291531.